Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > That was too easy, guess you missed it
View:
Post by Red~One on Jan 19, 2022 9:32am

That was too easy, guess you missed it

"“Additionally, we are negotiating to obtain exclusive worldwide rights to develop and commercialize R-107 for the treatment of skin ulcers and wound healing, including the treatment of severe burns."

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

V.CLAS | January 4, 2022
Comment by PTBailey on Jan 19, 2022 10:35am
 That was too easy, guess you missed it.  January 4 we were 'negotiating' for rights however, Jan.17 we announced that the negotiations are over and we "will enter into a new license agreement" Is this not a material development? "Claritas will enter into a new license agreement with Salzman Group for the development and commercialization of R-107 for the ...more  
Claritas Pharmaceuticals Inc